Lupron Depot Side Effects
Generic Name: Leuprolide
Please note - some side effects for Lupron Depot may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA at http://www.fda.gov/medwatch/ or 1-800-FDA-1088 (1-800-332-1088).
|
For the consumer
For the professional
|
|
Side Effects of Lupron Depot - for the consumer
Lupron Depot-PED
All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome when using Lupron Depot-PED:
Seek medical attention right away if any of these SEVERE side effects occur when using Lupron Depot-PED:Acne; breast enlargement; excessively oily skin; pain; vaginal bleeding or spotting; vaginal discharge; vaginal inflammation.
Severe allergic reactions (rash; hives; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); fainting; increased sexual maturity; irritation at the injection site; mood or mental changes.
Lupron Depot Depot Suspension
All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome when using Lupron Depot Depot Suspension:
Seek medical attention right away if any of these SEVERE side effects occur when using Lupron Depot Depot Suspension:Breast tenderness; constipation; decreased sex drive; difficulty sleeping; hot flashes/sweating; impotence; infection (fever, chills, sore throat); nausea or vomiting; pain, redness, or swelling at the injection site.
Severe allergic reactions (rash; hives; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); blood in urine; dizziness or lightheadedness; increase in bone pain; muscle weakness; paralysis; severe drowsiness; severe headache; shortness of breath; trouble urinating or inability to urinate; unusual or one-sided numbness or weakness; vision changes.
Lupron Depot Suspension
All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome when using Lupron Depot Suspension:
Seek medical attention right away if any of these SEVERE side effects occur when using Lupron Depot Suspension:Breast tenderness; constipation; decreased sex drive; difficulty breathing; difficulty sleeping; hot flashes/sweating; impotence; infection (fever, chills, sore throat); nausea or vomiting; pain; swelling; urination problems.
Severe allergic reactions (rash; hives; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); blood in urine; difficulty breathing; dizziness or lightheadedness; emphysema; increase in bone pain; severe drowsiness; severe headache; swelling of the lungs; unusual or one-sided weakness; vision changes.
Lupron Depot 3.75 mg Suspension
All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome when using Lupron Depot 3.75 mg Suspension:
Seek medical attention right away if any of these SEVERE side effects occur when using Lupron Depot 3.75 mg Suspension:Abnormal hair growth; abnormal skin sensations; acne; breast pain and tenderness; changes in breast size; changes in weight; decreased sex drive; depression; dizziness; headache; hot flashes/sweats; joint disorder; mood changes; muscle pain; nausea/vomiting; nervousness; pain; skin reactions; swelling; vaginal dryness; weakness.
Severe allergic reactions (rash; hives; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); continued vaginal bleeding; delusions; depression; dizziness; joint pain; memory loss; suicidal thoughts; swelling of the ankles or hands; weight gain or loss.
Lupron Depot 11.25 mg Suspension
All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome when using Lupron Depot 11.25 mg Suspension:
Seek medical attention right away if any of these SEVERE side effects occur when using Lupron Depot 11.25 mg Suspension:Abnormal hair growth; abnormal skin sensations; acne; breast pain and tenderness; changes in breast size;changes in bowel function; change in weight; decreased sex drive; dizziness; headache; hot flashes/sweats; mood changes; muscle or joint pain; nausea or vomiting; nervousness; trouble sleeping; vaginal dryness; weakness.
TopSevere allergic reactions (rash; hives; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); continued vaginal bleeding or menstrual periods; decreased urination; delusions; depression; fainting; fast or irregular heartbeat; memory problems; mental changes; severe or persistent mood changes; shortness of breath; suicidal thoughts; swelling of the ankles or hands.
For the professional
Lupron Depot
Clinical Trials
Estradiol levels may increase during the first weeks following the initial injection of LUPRON, but then decline to menopausal levels. This transient increase in estradiol can be associated with a temporary worsening of signs and symptoms.
As would be expected with a drug that lowers serum estradiol levels, the most frequently reported adverse reactions were those related to hypoestrogenism.
The monthly formulation of Lupron Depot 3.75 mg was utilized in controlled clinical trials that studied the drug in 166 endometriosis and 166 uterine fibroids patients. Adverse events reported in ≥5% of patients in either of these populations and thought to be potentially related to drug are noted in the following table.
| Endometriosis (2 Studies) | Uterine Fibroids (4 Studies) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Lupron Depot 3.75 mg N=166 |
Danazol N=136 |
Placebo N=31 |
Lupron Depot 3.75 mg N=166 |
Placebo N=163 |
||||||
| N | (%) | N | (%) | N | (%) | N | (%) | N | (%) | |
| In these same studies, symptoms reported in <5% of patients included: Body as a Whole - Body odor, Flu syndrome, Injection site reactions; Cardiovascular System - Palpitations, Syncope, Tachycardia; Digestive System - Appetite changes, Dry mouth, Thirst; Endocrine System - Androgen-like effects; Hemic and Lymphatic System - Ecchymosis, Lymphadenopathy; Nervous System– Anxiety*, Insomnia/Sleep disorders*, Delusions, Memory disorder, Personality disorder; Respiratory System - Rhinitis; Skin and Appendages - Alopecia, Hair disorder, Nail disorder; Special Senses - Conjunctivitis, Ophthalmologic disorders*, Taste perversion; Urogenital System - Dysuria*, Lactation, Menstrual disorders. | ||||||||||
| ||||||||||
| Body as a Whole | ||||||||||
| Asthenia | 5 | (3) | 9 | (7) | 0 | (0) | 14 | (8.4) | 8 | (4.9) |
| General pain | 31 | (19) | 22 | (16) | 1 | (3) | 14 | (8.4) | 10 | (6.1) |
| Headache* | 53 | (32) | 30 | (22) | 2 | (6) | 43 | (25.9) | 29 | (17.8) |
| Cardiovascular System | ||||||||||
| Hot flashes/sweats* | 139 | (84) | 77 | (57) | 9 | (29) | 121 | (72.9) | 29 | (17.8) |
| Gastrointestinal System | ||||||||||
| Nausea/vomiting | 21 | (13) | 17 | (13) | 1 | (3) | 8 | (4.8) | 6 | (3.7) |
| GI disturbances* | 11 | (7) | 8 | (6) | 1 | (3) | 5 | (3.0) | 2 | (1.2) |
| Metabolic and Nutritional Disorders | ||||||||||
| Edema | 12 | (7) | 17 | (13) | 1 | (3) | 9 | (5.4) | 2 | (1.2) |
| Weight gain/loss | 22 | (13) | 36 | (26) | 0 | (0) | 5 | (3.0) | 2 | (1.2) |
| Endocrine System | ||||||||||
| Acne | 17 | (10) | 27 | (20) | 0 | (0) | 0 | (0) | 0 | (0) |
| Hirsutism | 2 | (1) | 9 | (7) | 1 | (3) | 1 | (0.6) | 0 | (0) |
| Musculoskeletal System | ||||||||||
| Joint disorder* | 14 | (8) | 11 | (8) | 0 | (0) | 13 | (7.8) | 5 | (3.1) |
| Myalgia* | 1 | (1) | 7 | (5) | 0 | (0) | 1 | (0.6) | 0 | (0) |
| Nervous System | ||||||||||
| Decreased libido* | 19 | (11) | 6 | (4) | 0 | (0) | 3 | (1.8) | 0 | (0) |
| Depression/emotional lability* | 36 | (22) | 27 | (20) | 1 | (3) | 18 | (10.8) | 7 | (4.3) |
| Dizziness | 19 | (11) | 4 | (3) | 0 | (0) | 3 | (1.8) | 6 | (3.7) |
| Nervousness* | 8 | (5) | 11 | (8) | 0 | (0) | 8 | (4.8) | 1 | (0.6) |
| Neuromuscular disorders* | 11 | (7) | 17 | (13) | 0 | (0) | 3 | (1.8) | 0 | (0) |
| Paresthesias | 12 | (7) | 11 | (8) | 0 | (0) | 2 | (1.2) | 1 | (0.6) |
| Skin and Appendages | ||||||||||
| Skin reactions | 17 | (10) | 20 | (15) | 1 | (3) | 5 | (3.0) | 2 | (1.2) |
| Urogenital System | ||||||||||
| Breast changes/tenderness/pain* | 10 | (6) | 12 | (9) | 0 | (0) | 3 | (1.8) | 7 | (4.3) |
| Vaginitis* | 46 | (28) | 23 | (17) | 0 | (0) | 19 | (11.4) | 3 | (1.8) |
In one controlled clinical trial utilizing the monthly formulation of Lupron Depot, patients diagnosed with uterine fibroids received a higher dose (7.5 mg) of Lupron Depot. Events seen with this dose that were thought to be potentially related to drug and were not seen at the lower dose included glossitis, hypesthesia, lactation, pyelonephritis, and urinary disorders. Generally, a higher incidence of hypoestrogenic effects was observed at the higher dose.
Table 3 lists the potentially drug-related adverse events observed in at least 5% of patients in any treatment group during the first 6 months of treatment in the add-back clinical studies.
In the controlled clinical trial, 50 of 51 (98%) patients in the LD group and 48 of 55 (87%) patients in the LD/N group reported experiencing hot flashes on one or more occasions during treatment. During Month 6 of treatment, 32 of 37 (86%) patients in the LD group and 22 of 38 (58%) patients in the LD/N group reported having experienced hot flashes. The mean number of days on which hot flashes were reported during this month of treatment was 19 and 7 in the LD and LD/N treatment groups, respectively. The mean maximum number of hot flashes in a day during this month of treatment was 5.8 and 1.9 in the LD and LD/N treatment groups, respectively.
| Controlled Study | Open Label Study | |||||
|---|---|---|---|---|---|---|
| LD - Only* N=51 |
LD/N† N=55 |
LD/N† N=136 |
||||
| Adverse Events | N | (%) | N | (%) | N | (%) |
| Any Adverse Event | 50 | (98) | 53 | (96) | 126 | (93) |
| Body as a Whole | ||||||
| Asthenia | 9 | (18) | 10 | (18) | 15 | (11) |
| Headache/Migraine | 33 | (65) | 28 | (51) | 63 | (46) |
| Injection Site Reaction | 1 | (2) | 5 | (9) | 4 | (3) |
| Pain | 12 | (24) | 16 | (29) | 29 | (21) |
| Cardiovascular System | ||||||
| Hot flashes/sweats | 50 | (98) | 48 | (87) | 78 | (57) |
| Digestive System | ||||||
| Altered Bowel Function | 7 | (14) | 8 | (15) | 14 | (10) |
| Changes in Appetite | 2 | (4) | 0 | (0) | 8 | (6) |
| GI Disturbance | 2 | (4) | 4 | (7) | 6 | (4) |
| Nausea/Vomiting | 13 | (25) | 16 | (29) | 17 | (13) |
| Metabolic and Nutritional Disorders | ||||||
| Edema | 0 | (0) | 5 | (9) | 9 | (7) |
| Weight Changes | 6 | (12) | 7 | (13) | 6 | (4) |
| Nervous System | ||||||
| Anxiety | 3 | (6) | 0 | (0) | 11 | (8) |
| Depression/Emotional Lability | 16 | (31) | 15 | (27) | 46 | (34) |
| Dizziness/Vertigo | 8 | (16) | 6 | (11) | 10 | (7) |
| Insomnia/Sleep Disorder | 16 | (31) | 7 | (13) | 20 | (15) |
| Libido Changes | 5 | (10) | 2 | (4) | 10 | (7) |
| Memory Disorder | 3 | (6) | 1 | (2) | 6 | (4) |
| Nervousness | 4 | (8) | 2 | (4) | 15 | (11) |
| Neuromuscular Disorder | 1 | (2) | 5 | (9) | 4 | (3) |
| Skin and Appendages | ||||||
| Alopecia | 0 | (0) | 5 | (9) | 4 | (3) |
| Androgen-Like Effects | 2 | (4) | 3 | (5) | 24 | (18) |
| Skin/Mucous Membrane Reaction | 2 | (4) | 5 | (9) | 15 | (11) |
| Urogenital System | ||||||
| Breast Changes/Pain/Tenderness | 3 | (6) | 7 | (13) | 11 | (8) |
| Menstrual Disorders | 1 | (2) | 0 | (0) | 7 | (5) |
| Vaginitis | 10 | (20) | 8 | (15) | 11 | (8) |
In controlled clinical studies, patients with endometriosis (six months of therapy) or uterine fibroids (three months of therapy) were treated with Lupron Depot 3.75 mg. In endometriosis patients, vertebral bone density as measured by dual energy x-ray absorptiometry (DEXA) decreased by an average of 3.2% at six months compared with the pretreatment value. Clinical studies demonstrate that concurrent hormonal therapy (norethindrone acetate 5 mg daily) and calcium supplementation is effective in significantly reducing the loss of bone mineral density that occurs with LUPRON treatment, without compromising the efficacy of LUPRON in relieving symptoms of endometriosis.
Lupron Depot 3.75 mg plus norethindrone acetate 5 mg daily was evaluated in two clinical trials. The results from this regimen were similar in both studies. Lupron Depot 3.75 mg was used as a control group in one study. The bone mineral density data of the lumbar spine from these two studies are presented in Table 4.
| Lupron Depot 3.75mg | Lupron Depot 3.75 mg plus norethindrone acetate 5 mg daily | |||||
|---|---|---|---|---|---|---|
| Controlled Study | Controlled Study | Open Label Study | ||||
| N | Change | N | Change | N | Change | |
| Week 24* | 41 | -3.2% | 42 | -0.3% | 115 | -0.2% |
| Week 52† | 29 | -6.3% | 32 | -1.0% | 84 | -1.1% |
When Lupron Depot 3.75 mg was administered for three months in uterine fibroid patients, vertebral trabecular bone mineral density as assessed by quantitative digital radiography (QDR) revealed a mean decrease of 2.7% compared with baseline. Six months after discontinuation of therapy, a trend toward recovery was observed. Use of Lupron Depot for longer than three months (uterine fibroids) or six months (endometriosis) or in the presence of other known risk factors for decreased bone mineral content may cause additional bone loss and is not recommended.
Changes in Laboratory Values During TreatmentPlasma Enzymes
Endometriosis
During early clinical trials with Lupron Depot 3.75 mg, regular laboratory monitoring revealed that AST levels were more than twice the upper limit of normal in only one patient. There was no clinical or other laboratory evidence of abnormal liver function.
In two other clinical trials, 6 of 191 patients receiving Lupron Depot 3.75 mg plus norethindrone acetate 5 mg daily for up to 12 months developed an elevated (at least twice the upper limit of normal) SGPT or GGT. Five of the 6 increases were observed beyond 6 months of treatment. None were associated with elevated bilirubin concentration.
Uterine Leiomyomata (Fibroids)
In clinical trials with Lupron Depot 3.75 mg, five (3%) patients had a post-treatment transaminase value that was at least twice the baseline value and above the upper limit of the normal range. None of the laboratory increases were associated with clinical symptoms.
Lipids
Endometriosis
In earlier clinical studies, 4% of the Lupron Depot 3.75 mg patients and 1% of the danazol patients had total cholesterol values above the normal range at enrollment. These patients also had cholesterol values above the normal range at the end of treatment.
Of those patients whose pretreatment cholesterol values were in the normal range, 7% of the Lupron Depot 3.75 mg patients and 9% of the danazol patients had post-treatment values above the normal range.
The mean (±SEM) pretreatment values for total cholesterol from all patients were 178.8 (2.9) mg/dL in the Lupron Depot 3.75 mg groups and 175.3 (3.0) mg/dL in the danazol group. At the end of treatment, the mean values for total cholesterol from all patients were 193.3 mg/dL in the Lupron Depot 3.75 mg group and 194.4 mg/dL in the danazol group. These increases from the pretreatment values were statistically significant (p<0.03) in both groups.
Triglycerides were increased above the upper limit of normal in 12% of the patients who received Lupron Depot 3.75 mg and in 6% of the patients who received danazol.
At the end of treatment, HDL cholesterol fractions decreased below the lower limit of the normal range in 2% of the Lupron Depot 3.75 mg patients compared with 54% of those receiving danazol. LDL cholesterol fractions increased above the upper limit of the normal range in 6% of the patients receiving Lupron Depot 3.75 mg compared with 23% of those receiving danazol. There was no increase in the LDL/HDL ratio in patients receiving Lupron Depot 3.75 mg but there was approximately a two-fold increase in the LDL/HDL ratio in patients receiving danazol.
In two other clinical trials, Lupron Depot 3.75 mg plus norethindrone acetate 5 mg daily was evaluated for 12 months of treatment. Lupron Depot 3.75 mg was used as a control group in one study. Percent changes from baseline for serum lipids and percentages of patients with serum lipid values outside of the normal range in the two studies are summarized in the tables below.
| LUPRON | LUPRON plus norethindrone acetate 5 mg daily | |||||
|---|---|---|---|---|---|---|
| Controlled Study (n=39) | Controlled Study (n=41) | Open Label Study (n=117) | ||||
| Baseline Value* | Wk 24 % Change |
Baseline Value* | Wk 24 % Change |
Baseline Value* | Wk 24 % Change |
|
| Total Cholesterol | 170.5 | 9.2% | 179.3 | 0.2% | 181.2 | 2.8% |
| HDL Cholesterol | 52.4 | 7.4% | 51.8 | -18.8% | 51.0 | -14.6% |
| LDL Cholesterol | 96.6 | 10.9% | 101.5 | 14.1% | 109.1 | 13.1% |
| LDL/HDL Ratio | 2.0† | 5.0% | 2.1† | 43.4% | 2.3† | 39.4% |
| Triglycerides | 107.8 | 17.5% | 130.2 | 9.5% | 105.4 | 13.8% |
Changes from baseline tended to be greater at Week 52. After treatment, mean serum lipid levels from patients with follow up data returned to pretreatment values.
| LUPRON | LUPRON plus norethindrone acetate 5 mg daily | |||||
|---|---|---|---|---|---|---|
| Controlled Study (n=39) | Controlled Study (n=41) | Open Label Study (n=117) | ||||
| Wk 0 | Wk 24* | Wk 0 | Wk 24* | Wk 0 | Wk 24* | |
| ||||||
| Total Cholesterol (>240 mg/dL) | 15% | 23% | 15% | 20% | 6% | 7% |
| HDL Cholesterol (<40 mg/dL) | 15% | 10% | 15% | 44% | 15% | 41% |
| LDL Cholesterol (>160 mg/dL) | 0% | 8% | 5% | 7% | 9% | 11% |
| LDL/HDL Ratio (>4.0) | 0% | 3% | 2% | 15% | 7% | 21% |
| Triglycerides (>200 mg/dL) | 13% | 13% | 12% | 10% | 5% | 9% |
Low HDL-cholesterol (<40 mg/dL) and elevated LDL-cholesterol (>160 mg/dL) are recognized risk factors for cardiovascular disease. The long-term significance of the observed treatment-related changes in serum lipids in women with endometriosis is unknown. Therefore assessment of cardiovascular risk factors should be considered prior to initiation of concurrent treatment with LUPRON and norethindrone acetate.
Uterine Leiomyomata (Fibroids)
In patients receiving Lupron Depot 3.75 mg, mean changes in cholesterol (+11 mg/dL to +29 mg/dL), LDL cholesterol (+8 mg/dL to +22 mg/dL), HDL cholesterol (0 to +6 mg/dL), and the LDL/HDL ratio (-0.1 to +0.5) were observed across studies. In the one study in which triglycerides were determined, the mean increase from baseline was 32 mg/dL.
Other Changes
Endometriosis
The following changes were seen in approximately 5% to 8% of patients. In the earlier comparative studies, Lupron Depot 3.75 mg was associated with elevations of LDH and phosphorus, and decreases in WBC counts. Danazol therapy was associated with increases in hematocrit, platelet count, and LDH. In the hormonal add-back studies Lupron Depot in combination with norethindrone acetate was associated with elevations of GGT and SGPT.
Uterine Leiomyomata (Fibroids)
Hematology: In Lupron Depot 3.75 mg treated patients, although there were statistically significant mean decreases in platelet counts from baseline to final visit, the last mean platelet counts were within the normal range. Decreases in total WBC count and neutrophils were observed, but were not clinically significant.
Chemistry: Slight to moderate mean increases were noted for glucose, uric acid, BUN, creatinine, total protein, albumin, bilirubin, alkaline phosphatase, LDH, calcium, and phosphorus. None of these increases were clinically significant.
Postmarketing
During postmarketing surveillance, the following adverse events were reported. Like other drugs in this class, mood swings, including depression, have been reported. There have been rare reports of suicidal ideation and attempt. Many, but not all, of these patients had a history of depression or other psychiatric illness. Patients should be counseled on the possibility of development or worsening of depression during treatment with LUPRON.
Symptoms consistent with an anaphylactoid or asthmatic process have been rarely reported. Rash, urticaria, and photosensitivity reactions have also been reported.
Localized reactions including induration and abscess have been reported at the site of injection. Symptoms consistent with fibromyalgia (eg: joint and muscle pain, headaches, sleep disorder, gastrointestinal distress, and shortness of breath) have been reported individually and collectively. Other events reported are:
Cardiovascular System– Hypotension, Pulmonary embolism; Hemic and Lymphatic System - Decreased WBC; Central/Peripheral Nervous System - Peripheral neuropathy, Spinal fracture/paralysis; Musculoskeletal System - Tenosynovitis-like symptoms; Urogenital System - Prostate pain.
Pituitary apoplexyDuring post-marketing surveillance, rare cases of pituitary apoplexy (a clinical syndrome secondary to infarction of the pituitary gland) have been reported after the administration of gonadotropin-releasing hormone agonists. In a majority of these cases, a pituitary adenoma was diagnosed, with a majority of pituitary apoplexy cases occurring within 2 weeks of the first dose, and some within the first hour. In these cases, pituitary apoplexy has presented as sudden headache, vomiting, visual changes, ophthalmoplegia, altered mental status, and sometimes cardiovascular collapse. Immediate medical attention has been required.
See other Lupron Depot and LUPRON Injection package inserts for other events reported in different patient populations.
TopMore resources:
Lupron Depot - Includes detailed dosage instructions.
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This information does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of information provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.
